Our experts have participated in or led the development of five of the seven drugs approved by the US Food and Drug Administration for patients with advanced kidney cancer since 2005.
Dr. Dalbagni – who cares for patients with bladder cancer, kidney cancer, penile cancer, and sarcomas – explains treatments offered at Memorial Sloan-Kettering, which can help patients maintain their quality of life.
Dr. Parra, who practices at Memorial Sloan-Kettering Basking Ridge, treats prostate, kidney, and bladder cancers with the goal of extending the lives of patients, and giving them the best possible quality of life.
Dr. Bochner – who specializes in treating people with prostate, bladder, and kidney cancers – discusses the importance of a multidisciplinary team approach to delivering high-quality care.
Scientists have identified genes and biological mechanisms that one day could be targeted with drugs to stop kidney cancer from spreading to the bone, brain, or other organs.
Results of an international study indicate that the investigational drug tivozanib is more effective and better tolerated than a currently approved therapy in delaying cancer growth.
The recent FDA approval of axitinib provides a viable treatment option for patients who progress on or cannot tolerate the side effects of other approved drugs for the disease.
